Bristol-Myers Squibb Company (BMY) Q4 2009 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 0.82%

Bristol Myers Squibb's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 0.82%. This could be due to the lack of revenue data and no guidance for future performance, leaving investors uncertain about the company's direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.47	N/A	+9.05%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautious optimism about the future, emphasizing their commitment to innovation. However, they did not provide specific guidance for upcoming quarters.

Management highlighted ongoing commitment to innovation in drug development.

They expressed confidence in the pipeline but did not provide specific guidance.

The focus remains on delivering value to patients and stakeholders.

Bristol Myers Squibb Beats on EPS, Stock Down 0.82%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 0.82%

Key numbers

Management commentary